PPT-Tenecteplase Drugbank ID
Author : briana-ranney | Published Date : 2018-02-02
DB00031 Protein chemical formula C 2561 H 3919 N 747 O 781 S 40 Protein average weight 589512000 Half life 19 hours mammalian reticulocytes in vitro
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Tenecteplase Drugbank ID" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Tenecteplase Drugbank ID: Transcript
DB00031 Protein chemical formula C 2561 H 3919 N 747 O 781 S 40 Protein average weight 589512000 Half life 19 hours mammalian reticulocytes in vitro Description. Figure1:Schemainterlinkingforthreedatasetsi.e.DrugBank,Sider,Diseasome. Figure2:Resourcesfromthreedierentdatasetsarefusedattheinstancelevelinordertoexploitin-formationwhicharespreadacrossdiversedatas Colin Batchelor. ,. Ken Karapetyan, Valery Tkachenko, Antony Williams. 6th Joint Sheffield Conference on . Chemoinformatics. 2013-07-24. Overview. Open PHACTS and chemical validation and standardization. DB00005 . Half life : . 102 /- 30 hrs . Description. . :. Enbrel. (. etanercept. ) is a . dimeric. fusion protein consisting of the extracellular . ligand. -binding portion of the human 75 . kilodalton. : . DB00053. . Protein chemical . formula . : C. 2532. H. 3854. N. 672. O. 711. S. 16. Protein . average . weight :. 55597.4000. Half-life. . : . 3.6-10.4 min. . Description. . Human Beta-. glucocerebrosidase. DB00002 . Protein Chemical formula : . C. 6484. H. 10042. N. 1732. O. 2023. S. 36. . Protein Average . wt. . : . 145781.6 . Half life : . Approximately : . 114 hrs . Description. :. . Erbitux. is a targeted therapy. It is classified as a "monoclonal antibody" and "signal transduction inhibitor" by binding to epidermal growth factor receptors (EGFR).. DB00020 . Protein chemical . formula : . C. 639. H. 1006. N. 168. O. 196. S. 8. Protein . average . weight : . 14434.5000. Description. . :. Sargramostim. is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein. . ID . : . DB00019 . Protein chemical . formula : . C. 845. H. 1343. N. 223. O. 243. S. 9. Protein . average . weight : . 18802.8000. Half life : . 15-80 hrs . Description. . :. . PEGylated. (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation. . DB00021 . Protein chemical . formula . : C. 130. H. 219. N. 43. O. 42. Protein . average . weight : . 3056.4000. Chemical name : . H-His-Ser-Asp-. Gly. -. Thr. -. Phe. -. Thr. -Ser-. Glu. -. Leu. -Ser-. DB00059. . Protein chemical . formula : . C. 1377. H. 2208. N. 382. O. 442. S. 17. Protein . average . weight : . 31731.9000. Description. . : . Pegylated. . L-asparagine . amidohydrolase. from E. coli. . ID : . DB09560 . Indication. . :. Patients with Cancer Receiving . Myelosuppressive. Chemotherapy: to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with . Immunosuppressive Agents . RILONACEPT . . DESCRIPTION. INDICATION. Rilonacept. is a . dimeric. fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the . ID . : . DB00008 . Protein average . weight : . 60000.0000. . Half life : . Terminal half life is 80 hours (range 50 to 140 hours). . . Description. :. . Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched . MD FRCP. Acute Physician JPUH. 10 Questions to be answered. How do can we avoid investigating low risk patients?. How can we avoid testing in the elderly?. Is a dimer only helpful if it is negative?. DB09302. Description. :. Alirocumab. is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Download Document
Here is the link to download the presentation.
"Tenecteplase Drugbank ID"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents